SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : YellowLegalPad
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: John McCarthy1/5/2008 5:26:55 PM
   of 1182
 
Rik Picks

3 microcaps I like in the health care sector for 2008
are:

1. Corgenix Medical (CONX.ob) - .44. CONX has 51
FDA-approved medical diagnostic tests on the market
with the most recent AspirinWorks (AW) which is the
only non-invasive test available for aspirin tolerance
(there are some estimates that say up to 20% of the
population cannot tolerate aspirin). The co. has
stated that the AW product could be larger in terms of
revenues than all of its 50 other test kits being
sold. Awaiting FDA-approval since July, 2007 for its
newest cardiovascular test kit, Anti-AtherOx. Record
revenues and operating profit in its latest Q.

2. Northwest Biotherapeutics (NWBO.ob) - 2.44. Also
listed on the AIM in London. Awaiting Swiss approval
for DCVax-Brain for advanced brain cancer.

Uses dendritic cell (DC)technology which re-engineers a
patient's own cancer cells to fight the cancer.
Dendreon (DNDN-NASDAQ) has a similar DC technology
awaiting FDA approval for prostate cancer and has a
significantly higher market cap than NWBO. NWBO
recently began Phase I/II trials for ovarian cancer
which is being funded by the Ovarian Cancer Institute.

Its DCVax-Prostate is in Phase III trials in the US.
[This is NOT true]

Collins Stewart, a UK investment bank, has a buy
recommendation.

3. Generex (GNBT-NASDAQ) - 1.62. Recently approved
oral insulin product in India, United Arab Emirates
and Ecuador.

In Phase III trials in the US.

Awaiting approvals in several other countries.

Manufacturing
plant in Ecuador provides a significant cost advantage
for the company.

Big ramp-up is beginning due to
significant demand anticipated in India. Rodman &
Renshaw has a buy recommendation.

messages.finance.yahoo.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News